Research ExplorerPublicationsClinical efficacy and in vitro neutralization capacity of mo...

Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants

Standard

Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants. / Brehm, Thomas Theo; Pfefferle, Susanne; von Possel, Ronald; Karolyi, Mario; Zoufaly, Alexander; Wichmann, Dominic; Kobbe, Robin; Emmerich, Petra; Nörz, Dominik; Aepfelbacher, Martin; Schulze Zur Wiesch, Julian; Addo, Marylyn M; Schmiedel, Stefan; Lütgehetmann, Marc.

In: J MED VIROL, Vol. 94, No. 10, 10.2022, p. 5038-5043.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brehm, TT, Pfefferle, S, von Possel, R, Karolyi, M, Zoufaly, A, Wichmann, D, Kobbe, R, Emmerich, P, Nörz, D, Aepfelbacher, M, Schulze Zur Wiesch, J, Addo, MM, Schmiedel, S & Lütgehetmann, M 2022, 'Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants', J MED VIROL, vol. 94, no. 10, pp. 5038-5043. https://doi.org/10.1002/jmv.27916

APA

Brehm, T. T., Pfefferle, S., von Possel, R., Karolyi, M., Zoufaly, A., Wichmann, D., Kobbe, R., Emmerich, P., Nörz, D., Aepfelbacher, M., Schulze Zur Wiesch, J., Addo, M. M., Schmiedel, S., & Lütgehetmann, M. (2022). Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants. J MED VIROL, 94(10), 5038-5043. https://doi.org/10.1002/jmv.27916

Vancouver

Brehm TT, Pfefferle S, von Possel R, Karolyi M, Zoufaly A, Wichmann D et al. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants. J MED VIROL. 2022 Oct;94(10):5038-5043. https://doi.org/10.1002/jmv.27916

Bibtex

@article{b2c2b5cc62764378a31be71842fd5005,
title = "Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants",
abstract = "We aimed to provide in vitro data on the neutralization capacity of different monoclonal antibody (mAb) preparations against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta and omicron variant, respectively, and describe the in vivo RNA kinetics of coronavirus disease 2019 (COVID-19) patients treated with the respective mAbs. Virus neutralization assays were performed to assess the neutralizing effect of the mAb formulations casirivimab/imdevimab and sotrovimab on the SARS-CoV-2 delta and omicron variant. Additionally, respiratory tract SARS-CoV-2 RNA kinetics are provided for 25 COVID-19 patients infected with either delta variant (n = 18) or omicron variant (n = 7) treated with the respective mAb formulations during their hospital stay. In the virus neutralization assay, sotrovimab exhibits neutralizing capacity at therapeutically achievable concentrations against the SARS-CoV-2 delta and omicron variant. In contrast, casivirimab/imdevimab had neutralizing capacity against the delta variant but failed neutralization against the omicron variant except for a very high concentration above the currently recommended therapeutic dosage. In patients with delta variant infections treated with casivirimab/imdevimab, we observed a rapid decrease of respiratory viral RNA at day 3 after mAb therapy. In contrast, no such prompt decline was observed in patients with delta variant or omicron variant infections receiving sotrovimab.",
author = "Brehm, {Thomas Theo} and Susanne Pfefferle and {von Possel}, Ronald and Mario Karolyi and Alexander Zoufaly and Dominic Wichmann and Robin Kobbe and Petra Emmerich and Dominik N{\"o}rz and Martin Aepfelbacher and {Schulze Zur Wiesch}, Julian and Addo, {Marylyn M} and Stefan Schmiedel and Marc L{\"u}tgehetmann",
note = "{\textcopyright} 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.",
year = "2022",
month = oct,
doi = "10.1002/jmv.27916",
language = "English",
volume = "94",
pages = "5038--5043",
journal = "J MED VIROL",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants

AU - Brehm, Thomas Theo

AU - Pfefferle, Susanne

AU - von Possel, Ronald

AU - Karolyi, Mario

AU - Zoufaly, Alexander

AU - Wichmann, Dominic

AU - Kobbe, Robin

AU - Emmerich, Petra

AU - Nörz, Dominik

AU - Aepfelbacher, Martin

AU - Schulze Zur Wiesch, Julian

AU - Addo, Marylyn M

AU - Schmiedel, Stefan

AU - Lütgehetmann, Marc

N1 - © 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

PY - 2022/10

Y1 - 2022/10

N2 - We aimed to provide in vitro data on the neutralization capacity of different monoclonal antibody (mAb) preparations against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta and omicron variant, respectively, and describe the in vivo RNA kinetics of coronavirus disease 2019 (COVID-19) patients treated with the respective mAbs. Virus neutralization assays were performed to assess the neutralizing effect of the mAb formulations casirivimab/imdevimab and sotrovimab on the SARS-CoV-2 delta and omicron variant. Additionally, respiratory tract SARS-CoV-2 RNA kinetics are provided for 25 COVID-19 patients infected with either delta variant (n = 18) or omicron variant (n = 7) treated with the respective mAb formulations during their hospital stay. In the virus neutralization assay, sotrovimab exhibits neutralizing capacity at therapeutically achievable concentrations against the SARS-CoV-2 delta and omicron variant. In contrast, casivirimab/imdevimab had neutralizing capacity against the delta variant but failed neutralization against the omicron variant except for a very high concentration above the currently recommended therapeutic dosage. In patients with delta variant infections treated with casivirimab/imdevimab, we observed a rapid decrease of respiratory viral RNA at day 3 after mAb therapy. In contrast, no such prompt decline was observed in patients with delta variant or omicron variant infections receiving sotrovimab.

AB - We aimed to provide in vitro data on the neutralization capacity of different monoclonal antibody (mAb) preparations against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta and omicron variant, respectively, and describe the in vivo RNA kinetics of coronavirus disease 2019 (COVID-19) patients treated with the respective mAbs. Virus neutralization assays were performed to assess the neutralizing effect of the mAb formulations casirivimab/imdevimab and sotrovimab on the SARS-CoV-2 delta and omicron variant. Additionally, respiratory tract SARS-CoV-2 RNA kinetics are provided for 25 COVID-19 patients infected with either delta variant (n = 18) or omicron variant (n = 7) treated with the respective mAb formulations during their hospital stay. In the virus neutralization assay, sotrovimab exhibits neutralizing capacity at therapeutically achievable concentrations against the SARS-CoV-2 delta and omicron variant. In contrast, casivirimab/imdevimab had neutralizing capacity against the delta variant but failed neutralization against the omicron variant except for a very high concentration above the currently recommended therapeutic dosage. In patients with delta variant infections treated with casivirimab/imdevimab, we observed a rapid decrease of respiratory viral RNA at day 3 after mAb therapy. In contrast, no such prompt decline was observed in patients with delta variant or omicron variant infections receiving sotrovimab.

U2 - 10.1002/jmv.27916

DO - 10.1002/jmv.27916

M3 - SCORING: Journal article

C2 - 35662058

VL - 94

SP - 5038

EP - 5043

JO - J MED VIROL

JF - J MED VIROL

SN - 0146-6615

IS - 10

ER -